• 1
    Kelly MM, Leigh R, Jayaram L, Goldsmith CH, Nair P, Hargreave FE. Eosinophilic bronchitis in asthma: a model for establishing dose-response and relative potency of inhaled corticosteroids. J Allergy Clin Immunol 2006;117:989994.
  • 2
    Leigh R, Pizzichini MMM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J 2006;27:964971.
  • 3
    Pizzichini M, Pizzichini E, Nair P, Clelland L, Efthimiadis A, Dolovich J et al. Nonasthmatic chronic cough: no effect of treatment with an inhaled corticosteriod in patients without sputum eosinophilia. Can Respir J 1999;6:323330.
  • 4
    Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973984.
  • 5
    Castro M, Mathur S, Hargreave F, Boulet L-P, Xie F, Young J et al. Reslizumab for Poorly Controlled, Eosinophilic Asthma. Am J Respir Crit Care Med 2011;184:11251132.
  • 6
    Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360:985993.
  • 7
    Petsky HL, Cates CJ, Lasserson TJ, Li AM, Turner C, Kynaston JA et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67:199208.
  • 8
    Pizzichini E, Pizzichini M, Efthimiadis A, Hargreave F, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J 1996;9:11741180.
  • 9
    Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360:17151721.
  • 10
    Jayaram L, Pizzichini MM, Cook RJ, Boulet L-P, Lemière C, Pizzichini E et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483494.
  • 11
    Siva R, Green RH, Brightling CE, Shelley M, Hargadon B, McKenna S et al. Eosinophilic airway inflammation and exacerbations of COPD: a randomised controlled trial. Eur Respir J 2007;29:906913.
  • 12
    D'Silva L, Hassan N, Wang HY, Kjarsgaard M, Efthimiadis A, Hargreave FE et al. Heterogeneity of bronchitis in airway diseases in tertiary care clinical practice. Can Respir J 2011;18:144148.
  • 13
    Ochkur SI, Kim JD, Protheroe CA, Colbert D, Moqbel R, Lacy P et al. The development of a sensitive and specific ELISA for mouse eosinophil peroxidase: assessment of eosinophil degranulation ex vivo and in models of human disease. J Immunol Methods 2012;375:138147.
  • 14
    Cockcroft DW, Murdock KY, Kirby J, Hargreave F. Prediction of airway responsiveness to allergen from skin sensitivity to allergen and airway responsiveness to histamine. Am Rev Respir Dis 1987;135:264267.
  • 15
    Hargreave FE, Nair P. Point: is measuring sputum eosinophils useful in the management of severe asthma? Yes Chest 2011;139:12701273.
  • 16
    D'Silva L, Neighbour H, Gafni A, Radford K, Hargreave F, Nair P. Quantitative sputum cell counts to monitor bronchitis: a qualitative study of physician and patient perspectives. Can Respir J 2013;20:4751.
  • 17
    Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129(3 Suppl):S9S23.
  • 18
    Nair P, Kjarsgaard M, Armstrong S, Efthimiadis A, O'Byrne PM, Hargreave FE. Nitric oxide in exhaled breath is poorly correlated to sputum eosinophils in patients with prednisone-dependent asthma. J Allergy Clin Immunol 2010;126:404406.
  • 19
    Nair P. Eosinophil-targeted treatment of asthma. In: Lee JJ, Rosenberg HF, editors. Eosinophils in Health and Disease. Waltham: MA Elsevier, 2012; pp. 462466.
  • 20
    Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol 1998;63:715722.
  • 21
    Leigh R, Belda J, Kelly MM, Cox G, Squillace DL, Gleich GJ et al. Eosinophil cationic protein relates to sputum neutrophil counts in healthy subjects. J Allergy Clin Immunol 2000;106:593594.
  • 22
    Wassom DL, Loegering DA, Solley GO, Moore SB, Schooley RT, Fauci AS et al. Elevated serum levels of the eosinophil granule major basic protein in patients with eosinophilia. J Clin Invest 1981;67:651661.
  • 23
    Kato M, Kephart GM, Talley NJ, Wagner JM, Sarr MG, Bonno M et al. Eosinophil infiltration and degranulation in normal human tissue. Anat Rec 1998;252:418425.
  • 24
    Nakajima T, Matsumoto K, Suto H, Tanaka K, Ebisawa M, Tomita H et al. Gene expression screening of human mast cells and eosinophils using high-density oligonucleotide probe arrays: abundant expression of major basic protein in mast cells. Blood 2001;98:11271134.